{"id":972069,"date":"2026-06-15T08:34:45","date_gmt":"2026-06-15T12:34:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/"},"modified":"2026-06-15T08:34:45","modified_gmt":"2026-06-15T12:34:45","slug":"neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/","title":{"rendered":"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<ul type=\"disc\">\n<li>Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose<\/li>\n<li>Among participants who were overweight or obese at baseline, 37% achieved &gt;5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years<\/li>\n<li>Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment<\/li>\n<li>Patient\u2011reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well\u2011being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with CRENESSITY<\/li>\n<\/ul>\n<p>\n        <span class=\"legendSpanClass\">SAN DIEGO<\/span>, <span class=\"legendSpanClass\">June 15, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=2056102965&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.\" target=\"_blank\" rel=\"nofollow\">Neurocrine Biosciences, Inc.<\/a> (Nasdaq: NBIX) today announced new Phase 3 CAHtalyst<sup>\u00ae<\/sup> Adult study data demonstrating improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction through up to two years of treatment with <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=3124335684&amp;u=https%3A%2F%2Fwww.crenessity.com%2F&amp;a=CRENESSITY%C2%AE+(crinecerfont)\" target=\"_blank\" rel=\"nofollow\">CRENESSITY<sup>\u00ae<\/sup> (crinecerfont)<\/a> for classic congenital adrenal hyperplasia. These results, together with additional presentations highlighting improvement in bone outcomes and patient-reported quality of life survey outcomes, were presented at the\u00a0Endocrine Society&#8217;s annual meeting, ENDO\u00a02026, in Chicago.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674\" title=\"\" alt=\"\" \/>\n        <\/p>\n<\/p><\/div>\n<p>Long-term supraphysiologic glucocorticoid (GC) treatment in adults with classic congenital adrenal hyperplasia (CAH) is associated with obesity, insulin resistance, increased cardiometabolic risk and adverse effects on bone health. In these analyses, adults with classic CAH taking CRENESSITY for up to two years experienced improvements in weight, body composition and insulin resistance, key markers of long-term health, with sustained GC dose reductions and maintenance of baseline androgen control.<\/p>\n<p>&#8220;These two-year results provide important evidence on the long-term impact of CRENESSITY for adults living with classic congenital adrenal hyperplasia,&#8221; said Sanjay\u00a0Keswani,\u00a0M.D., Chief Medical Officer, Neurocrine Biosciences. &#8220;Sustained improvements across key clinical outcomes, including both cardiometabolic and bone outcomes, underscore the potential of CRENESSITY to meaningfully redefine lifelong disease management and improve health. We are excited to share these new data with the scientific community as we continue to deepen our understanding of the long-term impact of CRENESSITY on patient outcomes and quality of life.&#8221;<\/p>\n<p>CAHtalyst adult participants (N=182) who completed the 24-week, double-blind, placebo-controlled period and the subsequent six-month, open-label period of the study continued treatment with CRENESSITY in an ongoing open-label extension.<\/p>\n<p>\n        <i>Sustained Improvements in Weight\u2011related and Metabolic Outcomes over Two Years<\/i>\n      <\/p>\n<p>Cardiometabolic clinical outcomes were evaluated through up to two years of CRENESSITY treatment, including changes in body weight, body mass index (BMI), body composition and insulin resistance, as assessed by the homeostatic model assessment for insulin resistance (HOMA\u2011IR) at Months 12 and 24. To avoid potential confounding from glucagon-like peptide-1 (<span>GLP-1<\/span>) receptor agonists and\/or glucose-dependent insulinotropic polypeptide (GIP) use, data from participants taking these medications (n=9) were excluded from the time the medication was started.<\/p>\n<p>Sustained improvements were observed, with mean reductions from baseline in body weight, BMI and insulin resistance.<\/p>\n<ul type=\"disc\">\n<li>Among participants who were overweight or obese at baseline, more than one-third achieved clinically meaningful weight loss (&gt;5%) at two years, with reductions in fat mass exceeding changes in lean mass.<\/li>\n<li>Improvements in insulin resistance were also sustained through two years, including among participants with insulin resistance at baseline, 43% of whom were no longer insulin resistant at two years.<\/li>\n<\/ul>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Measure<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Baseline<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Change<br \/>from<br \/>Baseline at <br \/>Month<\/b>\u00a0<b>12<\/b><\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Change from<br \/>Baseline at<br \/>Month<\/b>\u00a0<b>24<\/b><\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Mean daily GC dose (mg\/m\u00b2\/day HCe*)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">17.6<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">-6.8<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(\u201137%)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">-7.0<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(\u201138%)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Mean BMI (kg\/m<sup>2<\/sup>)<sup>\u2020\u2021<\/sup><\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">32.5<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u20110.9<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u20110.9<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Percentage of overweight\/obese participants who<br \/>achieved &gt;5% reduction in weight<sup>\u2020\u2021<\/sup><\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u2014<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">31%<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(35\/114)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">37%<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(35\/95)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Change in percent fat mass versus percent lean<br \/>mass<sup>\u2020\u2021<\/p>\n<p><\/sup><\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u2014<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u20110.9%<br \/>versus<br \/>+0.7%<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u20110.9%<br \/>versus<br \/>+0.8%<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Mean HOMA\u2011IR<sup>\u2021\u00a7 <\/sup><\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">5.3<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u20111.5<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u20111.7<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Percentage of participants who achieved<br \/>HOMA-IR \u22642.5<sup>\u2021\u00a7<\/sup><\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">\u2014<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">40%<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(26\/65)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">43%<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(24\/56)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>*HCe denotes hydrocortisone equivalents.\u00a0<br \/><sup>\u2020<\/sup>Among participants who were overweight or obese (BMI \u226525 kg\/m<sup>2<\/sup>) at baseline. Clinically meaningful weight loss is defined as &gt;5% reduction in body weight.<br \/><sup>\u2021<\/sup>Data from participants who were taking a GIP\/<span>GLP-1<\/span> receptor agonist were excluded from the time the medication was started.<br \/><sup>\u00a7<\/sup>Among participants with insulin resistance (HOMA-IR &gt;2.5) at baseline.<\/p>\n<p>&#8220;For many adults with classic congenital adrenal hyperplasia, long\u2011term supraphysiologic glucocorticoid exposure can contribute to weight gain and insulin resistance, adding to cumulative cardiometabolic burden over time,&#8221; said Oksana Hamidi, D.O., M.S.C.S., Associate Professor of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center. &#8220;What makes these two-year data particularly meaningful is that they demonstrate sustained glucocorticoid reductions alongside improvements in insulin resistance and body composition, outcomes that are closely tied to future cardiometabolic risk and long-term health.&#8221;<\/p>\n<p>\n        <i>Favorable Trends Observed Across Bone-<\/i><br \/>\n        <i>related Outcomes<\/i>\n      <\/p>\n<p>Bone\u2011related outcomes were also assessed over two years of CRENESSITY treatment, including bone mineral density (BMD) <i>z<\/i> scores at Months 12, 18 and 24, and mean changes from baseline in bone turnover markers at Months 12 and 18.<\/p>\n<p>Favorable trends were observed in mineral density measurements (lumbar spine and total hip) and bone turnover (formation\/resorption).<\/p>\n<ul type=\"disc\">\n<li>BMD <i>z<\/i> scores trended toward incremental improvement over time, with the greatest improvement in the lumbar spine where there is the largest proportion of GC-sensitive bone.<\/li>\n<li>All bone turnover markers increased from baseline to Month 12, potentially reflecting recovery from suppression caused by supraphysiologic GC doses.<\/li>\n<li>From Month 12 to Month 18, markers of bone formation remained at similar levels, while markers of bone resorption showed a decreasing trend.<\/li>\n<\/ul>\n<p>\n        <i>Patient<\/i>\u2011<i>reported Survey Data Reflect Meaningful Changes in Lived Experience<\/i><\/p>\n<p>To understand patient perspectives following long\u2011term CRENESSITY treatment, a cross\u2011sectional survey was conducted among adult U.S. participants (n=48) at their final open-label extension visit.<\/p>\n<p>In the survey, 96% of respondents indicated they were moderately or very satisfied with their experience with CRENESSITY treatment, and a majority of participants reported:<\/p>\n<ul type=\"disc\">\n<li>Having more hope for their future living with classic CAH (98%).<\/li>\n<li>Feeling more in control of their classic CAH (94%).<\/li>\n<li>Being more optimistic about reducing the long-term impacts of high-dose GCs (96%) and elevated adrenocorticotropic hormone or androgens (92%).<\/li>\n<\/ul>\n<p>Large majorities of participants who experienced improvements also reported those changes as meaningful, including less side effects associated with high-dose steroids (93%) and less worry about weight gain associated with high-dose steroids (81%), as well as high levels of treatment satisfaction, with 98% reporting they would recommend CRENESSITY and 96% reporting they preferred treatment with CRENESSITY over treatment without CRENESSITY.<\/p>\n<p>Across analyses, CRENESSITY was generally well tolerated through up to two years of treatment, with no new safety signals observed during long\u2011term follow\u2011up.<\/p>\n<p>These findings build on two\u2011year data presented earlier this year at the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=3560467566&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-presents-new-two-year-crenessityr&amp;a=American+Association+of+Clinical+Endocrinology+2026+Annual+Meeting\" target=\"_blank\" rel=\"nofollow\">American Association of Clinical Endocrinology 2026 Annual Meeting<\/a> and the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=918620486&amp;u=https%3A%2F%2Fneurocrine.gcs-web.com%2Fnews-releases%2Fnews-release-details%2Fneurocrine-biosciences-presents-new-two-year-crenessityr-0&amp;a=Pediatric+Endocrine+Society+2026+Annual+Meeting\" target=\"_blank\" rel=\"nofollow\">Pediatric Endocrine Society 2026 Annual Meeting<\/a> in adults and pediatrics, respectively.<\/p>\n<p>\n        <b>Presentations at the ENDO 2026 annual meeting included: <\/b>\n      <\/p>\n<p>\n        <u>CAHtalyst Adult Study Two-Year Results<\/u>\n      <\/p>\n<p>\n        <b>Title:<\/b> Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study <b>(Oral Presentation #ORF32-07)<br \/><\/b><b>Authors: <\/b>Oksana Hamidi, D.O., et al<\/p>\n<p>\n        <b>Title:<\/b> Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study <b>(Poster Presentation #SUN-458)<br \/><\/b><b>Authors: <\/b>Irina Bancos, M.D., et al<\/p>\n<p>\n        <b>Title:<\/b> A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia in the United States Participating in CAHtalyst Adult Open-Label Extension Study <b>(Poster Presentation #SUN-467)<br \/><\/b><b>Authors: <\/b>Sonal Vaid, M.D., et al<\/p>\n<p>\n        <b>Title:<\/b> Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study <b>(Poster Presentation #SUN-468)<br \/><\/b><b>Authors: <\/b>Maria Vogiatzi, M.D., et al<\/p>\n<p>\n        <u>CAHtalyst Pediatric Study Two-Year Results<\/u>\n      <\/p>\n<p>\n        <b>Title:<\/b> Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont <b>(Oral Presentation #ORF32-05)<br \/><\/b><b>Authors: <\/b>Maria Vogiatzi, M.D., et al<\/p>\n<p>\n        <b>Title:<\/b> Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone \u2014 Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric <b>(Poster Presentation #SAT-465)<br \/><\/b><b>Authors: <\/b>Natalie Nokoff, M.D., et al<\/p>\n<p>\n        <b>Title:<\/b> Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses \u2014 Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric <b>(Poster Presentation #SUN-465)<br \/><\/b><b>Authors: <\/b>Kyriakie Sarafoglou, M.D., et al<\/p>\n<p>\n        <u>Additional Presentations<\/u>\n      <\/p>\n<p>\n        <b>Title:<\/b> Long-term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry <b>(&#8220;New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency&#8221; Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)<br \/><\/b><b>Authors: <\/b>Oksana Lekarev, D.O., et al<\/p>\n<p>\n        <b>Title:<\/b> Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11\u03b2-Hydroxylase Deficiency: A Case Series<b> (Poster Presentation #SAT-466)<br \/><\/b><b>Authors: <\/b>Kyriakie Sarafoglou, M.D., et al<\/p>\n<p>\n        <b>Title:<\/b> A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia <b>(Poster Presentation #SAT-459)<br \/><\/b><b>Authors: <\/b>Ahmed Khattab, M.D., et al<\/p>\n<p>\n        <b>About Congenital Adrenal Hyperplasia<\/b>\u00a0<br \/>Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone.\u00a0Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.<\/p>\n<p>Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens.\u00a0However, GC treatment at\u00a0supraphysiologic\u00a0doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular\u00a0disease\u00a0and osteoporosis. Additionally, long-term treatment with\u00a0supraphysiologic\u00a0GCs may have psychological and cognitive impacts, such as changes in mood and memory.\u00a0Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to\u00a0cardiometabolic and\u00a0fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).\u00a0<\/p>\n<p>\n        <b>About CRENESSITY<\/b><br \/>\n        <b><br \/>\n          <sup>\u00ae<\/sup><br \/>\n        <\/b>\u00a0<b>(crinecerfont)<\/b><br \/>CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.<\/p>\n<p>CRENESSITY comes in capsules and an oral solution. For adults 18 years\u202fof age\u202fand older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121\u202flbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121\u202flbs), the recommended dosage is\u202f100 mg\u202ftwice daily taken orally with a meal. Healthcare providers can work with patients to\u202fdetermine\u202fthe\u202fappropriate formulation\u202ffor use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.\u202f<\/p>\n<p>\n        <b>About the<\/b>\u00a0<b>CAHtalyst<\/b><b><sup>\u00ae<\/sup><\/b><b> Studies<\/b><br \/>The Phase 3\u202fCAHtalyst\u202fglobal registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY<sup>\u00ae<\/sup> (crinecerfont)\u202fin children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The\u202fCAHtalyst\u202fstudies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.<\/p>\n<p>The\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=47327309&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2F10.1056%2FNEJMoa2404655&amp;a=%C2%A0\" target=\"_blank\" rel=\"nofollow\">\u00a0<\/a><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=2963268415&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2F10.1056%2FNEJMoa2404655&amp;a=CAHtalyst%C2%A0Pediatric+study\" target=\"_blank\" rel=\"nofollow\">CAHtalyst\u00a0Pediatric study<\/a>\u00a0included 103 pediatric\u202fpatients\u202ffour to 17 years\u202fof age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional\u202f24 weeks\u202fof CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were\u202fmaintained\u202for improved.<\/p>\n<p>The\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=2214498377&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2404656&amp;a=CAHtalyst+Adult+study\" target=\"_blank\" rel=\"nofollow\">CAHtalyst Adult study<\/a> included 182 adult patients 18 to 58 years\u202fof age. Similarly, the first question of the study evaluated whether four weeks of\u00a0CRENESSITY treatment could improve androgen control, and the second question evaluated whether an\u202fadditional\u202f20 weeks\u202fof CRENESSITY treatment enabled GC reduction to\u202fphysiologic\u202frange while androstenedione levels were\u202fmaintained\u202for improved.<\/p>\n<p>Data from the\u202fCAHtalyst\u202fPhase 3 studies supported approval of CRENESSITY by the\u202fU.S.\u202fFood and Drug Administration\u202fin\u202fDecember 2024. The\u202fopen-label extension treatment portions of both studies are ongoing.<\/p>\n<p>\n        <b>Important Information<\/b>\n      <\/p>\n<p>\n        <b>Approved Uses<br \/><\/b>CRENESSITY<sup>\u00ae<\/sup> (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).\u202f<\/p>\n<p>\n        <b>IMPORTANT SAFETY INFORMATION<\/b>\n      <\/p>\n<p>\n        <b>Do not take CRENESSITY if you:<\/b>\u202f<\/p>\n<p>Are allergic to\u202fcrinecerfont, or any of the ingredients in CRENESSITY.<\/p>\n<p>\n        <b>CRENESSITY may cause serious side effects, including:<\/b>\n      <\/p>\n<p>\n        <b>Allergic\u202freactions.\u202f<\/b>Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.\u202f<\/p>\n<p>\n        <b>Risk of Sudden Adrenal Insufficiency or Adrenal Crisis\u202fwith\u202fToo Little Glucocorticoid (Steroid) Medicine.\u202f<\/b>Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk\u202ffor\u202fsudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.\u202f<\/p>\n<p>\n        <b>Before taking CRENESSITY, tell your healthcare provider about<\/b>\u00a0<b>all of<\/b>\u00a0<b>your medical conditions, including if<\/b>\u00a0<b>you:\u202f<\/b>are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.<\/p>\n<p>\n        <b>Tell your healthcare provider about all the medicines you take,\u202f<\/b>including prescription and over-the-counter medicines, vitamins and herbal supplements.<\/p>\n<p>\n        <b>The most common side effects of CRENESSITY in adults include\u202f<\/b>tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.<\/p>\n<p>\n        <b>The most common side effects of CRENESSITY in children include<\/b>\u202fheadache, stomach pain, tiredness, nasal congestion, and nosebleeds.<\/p>\n<p>These are not all the possible\u202fside effects of CRENESSITY. Call your healthcare provider for medical advice\u202fabout\u202fside effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch\u202fat\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=1987522321&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4325283-1%26h%3D2561209654%26u%3Dhttp%253A%252F%252Fwww.fda.gov%252Fmedwatch%26a%3Dwww.fda.gov%252Fmedwatch&amp;a=www.fda.gov%2Fmedwatch\" target=\"_blank\" rel=\"nofollow\">www.fda.gov\/medwatch<\/a>\u202for call 1-800-FDA-1088.<\/p>\n<p>\n        <b>Dosage Forms and Strengths:\u202f<\/b>CRENESSITY is available in 50 mg and\u202f100 mg\u202fcapsules,\u202fand as an oral solution of\u202f50 mg\/mL.<\/p>\n<p>Please see full\u202f<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=2190460635&amp;u=https%3A%2F%2Fpi.neurocrine.com%2Fcrenessity%2FCRENESSITY-Full-US-Prescribing-Information.pdf&amp;a=Prescribing+Information\" target=\"_blank\" rel=\"nofollow\"><b>Prescribing Information<\/b><\/a>.<\/p>\n<p>\n        <b>About Neurocrine<\/b>\u00a0<b>Biosciences, Inc.<\/b>\u00a0<br \/>Neurocrine Biosciences\u00a0is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders.\u00a0The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington&#8217;s disease, classic congenital\u00a0adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=1513082178&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4701734-1%26h%3D3085014877%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D4039787179%2526u%253Dhttps%25253A%25252F%25252Fwww.neurocrine.com%25252F%2526a%253Dneurocrine.com%26a%3Dneurocrine.com&amp;a=neurocrine.com\" target=\"_blank\" rel=\"nofollow\">neurocrine.com<\/a>, and follow the company on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=2479486444&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fneurocrine%2Fposts%2F%3FfeedView%3Dall&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=3632785892&amp;u=https%3A%2F%2Fx.com%2Fneurocrine&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=3539011455&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4701734-1%26h%3D1580692651%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4325283-1%2526h%253D2508503173%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4252873-1%252526h%25253D1536396415%252526u%25253Dhttps%2525253A%2525252F%2525252Fwww.facebook.com%2525252FNeurocrine%252526a%25253DFacebook%2526a%253DFacebook%26a%3DFacebook&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a> and <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4710879-1&amp;h=3208569215&amp;u=https%3A%2F%2Fwww.youtube.com%2F%40NeurocrineBiosciencesInc&amp;a=YouTube\" target=\"_blank\" rel=\"nofollow\">YouTube<\/a>.\u00a0<i>(*in collaboration with AbbVie)<\/i><\/p>\n<p>The\u00a0NEUROCRINE\u00a0BIOSCIENCES Logo,\u00a0NEUROCRINE, YOU\u00a0DESERVE BRAVE SCIENCE, CRENESSITY\u00a0and CAHtalyst are\u00a0registered trademarks of Neurocrine Biosciences, Inc.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\u00a0<br \/>In addition to historical facts, this press release\u00a0contains\u00a0forward-looking statements that involve\u00a0a number of\u00a0risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential support sustained glucocorticoid dose reductions and contribute to improvements in certain cardiometabolic, bone health and patient-reported outcomes;\u00a0the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY; risks\u00a0and uncertainties associated with Neurocrine Biosciences&#8217; business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company&#8217;s dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company&#8217;s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company&#8217;s quarterly report on Form 10-Q for the quarter ended\u00a0March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.<\/p>\n<p>\u00a9\u00a02026\u00a0Neurocrine Biosciences, Inc. All Rights Reserved. CAP-CFT-US-0063 06\/2026<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA83033&amp;sd=2026-06-15\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2026-302799744.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2026-302799744.html<\/a><\/p>\n<p>SOURCE Neurocrine Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA83033&amp;Transmission_Id=202606150830PR_NEWS_USPR_____LA83033&amp;DateId=20260615\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved &gt;5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment Patient\u2011reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well\u2011being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-972069","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved &gt;5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment Patient\u2011reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well\u2011being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with &hellip; Continue reading &quot;Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T12:34:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026\",\"datePublished\":\"2026-06-15T12:34:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/\"},\"wordCount\":3033,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2704674\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/\",\"name\":\"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2704674\",\"datePublished\":\"2026-06-15T12:34:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2704674\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2704674\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/","og_locale":"en_US","og_type":"article","og_title":"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Market Newsdesk","og_description":"PR Newswire Two-year CRENESSITY data in adults showed improvements in cardiometabolic outcomes of insulin resistance, body composition and body weight alongside sustained reductions in glucocorticoid dose Among participants who were overweight or obese at baseline, 37% achieved &gt;5% reduction in body weight at 2 years, and 43% of those with insulin resistance at baseline were no longer insulin resistant at 2 years Favorable trends in bone health outcomes were observed with CRENESSITY treatment, including improvements in bone mineral density with up to 2 years of treatment Patient\u2011reported survey data from adults in the open-label extension suggested improvements in quality of life outcomes and treatment satisfaction, including emotional well\u2011being, energy levels and confidence in managing their classic congenital adrenal hyperplasia with &hellip; Continue reading \"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-15T12:34:45+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026","datePublished":"2026-06-15T12:34:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/"},"wordCount":3033,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/","name":"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674","datePublished":"2026-06-15T12:34:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2704674"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-improvements-in-cardiometabolic-outcomes-in-adults-with-classic-congenital-adrenal-hyperplasia-at-endo-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences Presents New Two-Year CRENESSITY\u00ae (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=972069"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/972069\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=972069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=972069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=972069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}